Caltech-led Team Provides Proof in Humans of RNA Interference Using Targeted Nanoparticles
Up one levelResearchers unveil scientific results from siRNA Phase I clinical trial in cancer patients
Article published on the Caltech Media Relations webpage
PASADENA, Calif.—A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticle—used as an experimental therapeutic and injected directly into a patient’s bloodstream—can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi). Moreover, the team provided the first demonstration that this new type of therapy, infused into the bloodstream, can make its way to human tumors in a dose-dependent fashion—i.e., a higher number of nanoparticles sent into the body leads to a higher number of nanoparticles in the tumor cells...
Read the full article on:
